Y mAbs Therapeutics — Q3 2024 Earnings Presentation
20 slides from Y mAbs Therapeutics's earnings presentation, Nov 8, 2024
Slide 1: Q3 2024 Financial Results and Corporate Update
Q3 2024 Financial Results and Corporate Update November 8, 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this pre
Slide 3: Intro and Company Overview
Mike Rossi President and CEO Intro and Company Overview 3
Slide 4: Agenda
Agenda Company Overview 1 Mike Rossi, President and Chief Executive Officer DANYELZA Global Sales 2 Sue Smith, Chief Commercial Officer Naxitamab Development Program 3 Vignesh Rajah, Chief Medical Officer Q3 2024 Financials 4 Peter Pfreundschuh, Chief Financial Officer Q&A 5 All 4
Slide 5: Q3 2024 & Recent Corporate Highlights
Q3 2024 & Recent Corporate Highlights • Increasing DANYELZA demand and physician adoption • Q3 2024 Total Net Revenues of $18.5M, 10% YoY • Nine months 2024 Total Net Revenues of $61.2M, relatively flat YoY • Received notification of the accepted patent extension for DANYELZA, US 9,315,585, throug
Slide 6: GD2-SADA Phase Clinical Trial (Study 1001): Dosing Patients in Part A
GD2-SADA Phase 1 Clinical Trial (Study 1001): Dosing Patients in Part A Theranostic approach using a 30 mCi 177Lu-DOTA imaging dose before exposing to therapeutic dose Part A* Part B Part C Inclusion Criteria N ≈ 15 – 18 N ≈ 9 – 12 5 cycles 177Lu-DOTA therapeutic • ECOG performance GD2-SADA protein
Slide 7: Ongoing GD2-SADA Phase Clinical Trial (Study 1001): Part A Overview
Ongoing GD2-SADA Phase 1 Clinical Trial (Study 1001): Part A Overview TRIAL UPDATE PART A DATA ELEMENTS › Solid tumors (SCLC, malignant melanoma, sarcomas, adult neuroblastoma) • Optimal and safe GD2-SADA protein dose › Completed Cohorts 1 through 5; currently in Cohort 6* • Dosing interval between
Slide 8: CD38-SADA Phase Clinical Trial (Study 1201): Trial Design
CD38-SADA Phase 1 Clinical Trial (Study 1201): Trial Design Theranostic approach using CD38 positivity on IHC and 177Lu-DOTA organ dosimetry before repeat dosing in patients with relapsed or refractory non-Hodgkin Lymphoma Part A Part B N = 12 – 15 N = 12 – 15 Inclusion Criteria TRIAL UPDATE • R/R n
Slide 9: Global DANYELZA Sales
Sue Smith Chief Commercial Officer Global DANYELZA Sales 9
Slide 10: Q3 2024 DANYELZA Global Commercial Update
Q3 2024 DANYELZA Global Commercial Update • Q324 US DANYELZA Vial sales Q3 2024 U.S. DANYELZA Net Product Revenues of $15.3M, 5% YoY • Q3 2024 Ex-U.S. DANYELZA Net Product Revenues of $3.1M, 19% YoY • 68 U.S. accounts* since initial launch; 3 new accounts added in Q3 2024 • 34 U.S. HCPs prescrib
Slide 11: Naxitamab Development Program
Vignesh Rajah Chief Medical Officer Naxitamab Development Program 11
Slide 12: Ongoing Naxitamab Clinical Trials
Ongoing Naxitamab Clinical Trials • Multi-center Phase 2 trial • Phase 2 BCC multi-center • Phase 1b trial investigating • Randomized Phase 2 trial investigating naxitamab trial evaluating naxitamab TGFβ NKs, gemcitabine + evaluating efficacy and in patients with relapsed + standard induction naxita
Slide 13: Q3 2024 Financials
Peter Pfreundschuh Chief Financial Officer Q3 2024 Financials 13
Slide 14: Key Q3 2024 and YTD Financial Highlights: Revenue
Key Q3 2024 and YTD Financial Highlights Revenue Three months ended Sep 30, Nine months ended Sep 30, 2024 2023 2024 2023 Net product revenue $18.5 M $20.0 M Net product revenue $60.7 M $61.0 M License revenue – $0.5 License revenue $0.5 $0.5 Total revenue $18.5 M $20.5 M Total revenue $61.2 M $61.5
Slide 15: Key Q3 2024 and YTD Financial Highlights: Operating Expenses
Key Q3 2024 and YTD Financial Highlights Operating Expenses Three months ended Sep 30, Nine months ended Sep 30, 2024 2023 2024 2023 Cost of goods sold $2.3 M $2.6 M Cost of goods sold $7.4 M $9.3 M License royalties – $0.05 M License royalties $0.05 M $0.05 M Research & development $11.2 M $15.4 M
Slide 16: Key Q3 2024 and YTD Financial Highlights: Net Loss
Key Q3 2024 and YTD Financial Highlights Net Loss Three months ended Sep 30, Nine months ended Sep 30, 2024 2023 2024 2023 Net loss $(7.0) M $(7.7) M Net loss $(22.9) M $(20.4) M Net loss per basic, diluted share $(0.16) $(0.18) Net loss per basic, diluted share $(0.52) $(0.47) Net loss Net loss 9
Slide 17: Key Q3 2024 Financial Highlights
Key Q3 2024 Financial Highlights Responsible stewards of capital As of Nine months ended Sep 30, Sep 30, 2024 Dec 31, 2023 2024 2023 Cash and cash equivalents $68.1 M $78.6 M Cash use $10.5 M $19.2 M Anticipated cash runway Cash investment into 2027* 45% YoY *This estimate reflects the Company's c
Slide 18: Reiterate Financial Guidance for Full Year 2024
Reiterate Financial Guidance for Full Year 2024 Total Expected Net Revenues: $87 million to $95 million Total Expected Operating Expenses: $115 million to $120 million Total Expected Cash Investment: $15 million to $20 million Cash and cash equivalents anticipated to support operations as currently
Slide 19: Q&A
Q&A Mike Rossi Sue Smith President and Chief Commercial Officer Chief Executive Officer Vignesh Rajah, MBBS, Peter Pfreundschuh DCH, MRCP Chief Financial Officer Chief Medical Officer 19
Slide 20: Thank You
Thank You